CELLPATH LIMITED

Here is the credit analysis for CELLPATH LIMITED.

1. Credit Opinion: CONDITIONAL APPROVE

Reasoning: The company presents a structurally sound business with a long operational history (since 1984) in a specialized medical/laboratory supply niche. The primary strength is its membership in a corporate group (Cellpath Holdings Limited), which provides implicit financial support. However, as an "Audit Exemption Subsidiary," there are no filed financial accounts available for independent review. This lack of transparent financial data is the principal risk. Approval should be conditional on obtaining a Group Guarantee from the parent company and reviewing management accounts for the last 12-24 months to verify cash flow and profitability.

2. Financial Strength

• Structure: The company was previously a PLC (Public Limited Company) and has a substantial issued share capital (£60,200), indicating a formal capital structure.
• Leverage & Solvency: Without filed accounts, we cannot calculate gearing or net worth. However, the parent company (Cellpath Holdings Limited) holds 100% control, suggesting the subsidiary's balance sheet is likely consolidated. The risk is that the subsidiary may be thinly capitalized or heavily intercompany-indebted.
• Key Risk: No financial data available. The company files as an "Audit Exemption Subsidiary," meaning it relies on the parent's guarantee for exemption. This makes independent credit scoring impossible.

3. Cash Flow Assessment

• Liquidity: We cannot calculate current ratio, quick ratio, or assess working capital from the available data.
• Operating Cycle: The business involves manufacturing and wholesale of specialized laboratory consumables (histopathology/cytology). This typically requires moderate inventory holding and trade debtor cycles. Without financials, we cannot confirm if the company is self-financing or reliant on parent funding.
• Key Risk: Invisible cash position. We cannot determine if the company has sufficient cash to service a standalone loan or if it is dependent on intra-group cash pooling.

4. Monitoring Points (If Credit is Extended)

If a facility is granted based on a parent guarantee, the following must be monitored: 1. Parent Company Accounts: Request and review the consolidated accounts of Cellpath (Holdings) Limited annually. The health of the subsidiary is entirely dependent on the parent. 2. Management Accounts: Require quarterly management accounts (P&L and Balance Sheet) for Cellpath Limited to verify trading performance and working capital trends. 3. Director Changes: Watch for any resignation of key directors (Xxxxxx Xxxxxxxxname shown to subscribers, Xxxxxx Xxxxxxxxname shown to subscribers) as this could signal a change in group strategy or distress. 4. Group Structure: Monitor for any changes in the PSC (Cellpath Holdings) or signs that the subsidiary is being wound down or sold.

Executive Summary: Cellpath Limited is a long-established, specialized manufacturer in the medical diagnostics sector, wholly owned by a holding company. The primary credit risk is the complete absence of standalone financial accounts, making independent financial assessment impossible. We recommend a CONDITIONAL APPROVAL, strictly contingent on receiving a legally enforceable Parent Company Guarantee from Cellpath (Holdings) Limited and a review of recent management accounts. Without these, the facility should be declined due to insufficient data.

Names of the people mentioned are shown to subscribers. See subscription